Department of Urology, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA.
J Endourol. 2010 Oct;24(10):1687-91. doi: 10.1089/end.2010.0029.
To study short- and intermediate-term global renal function in patients undergoing a single percutaneous radiofrequency ablation (pRFA) for a solitary renal parenchymal tumor.
We reviewed the records of 62 patients who underwent a single pRFA for solitary renal parenchymal tumor. We used the abbreviated Modified Diet for Renal Disease equation to calculate baseline, 1-month, and 1-year glomerular filtration rate (GFR). We defined normal as >60, moderately diminished as 45-60, and severely diminished GFR as <45 cc/minute/1.73 m². We used the Wilcoxon paired rank sum method to compare 1-month and 1-year GFR to baseline. We fit a linear regression model to test the association of lesion size to GFR controlling for lesion location and baseline GFR.
There was no difference in GFR from baseline at 1 month or 1 year (55 vs. 58 cc/minute/1.73 m², p=0.24 and 55 vs. 57 cc/minute/1.73 m², p=0.8, respectively). Tumor size did not affect GFR at 1 month or 1 year after controlling for lesion location and baseline GFR.
A single application of pRFA does not affect GFR in the short or intermediate term.
研究单次经皮射频消融（pRFA）治疗单个肾实质肿瘤患者的短期和中期整体肾功能。
我们回顾了 62 例行单次 pRFA 治疗单个肾实质肿瘤患者的病历。我们使用简化的肾脏病饮食改良公式计算肾小球滤过率（GFR）的基线值、1 个月和 1 年值。我们将正常定义为>60，中度降低为 45-60，严重降低为<45cc/min/1.73m²。我们使用 Wilcoxon 配对秩和检验比较 1 个月和 1 年的 GFR 与基线值。我们拟合线性回归模型，以检验病变大小与 GFR 的关联，同时控制病变位置和基线 GFR。
1 个月和 1 年时的 GFR 与基线值相比没有差异（55 与 58cc/min/1.73m²，p=0.24 和 55 与 57cc/min/1.73m²，p=0.8）。控制病变位置和基线 GFR 后，肿瘤大小对 1 个月和 1 年时的 GFR 没有影响。
单次应用 pRFA 在短期和中期内不会影响 GFR。
